过去二十年印度幽门螺杆菌的原发性抗生素耐药性:系统回顾。

IF 4.3 2区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Helicobacter Pub Date : 2024-02-28 DOI:10.1111/hel.13057
Spriha Dutta, Surbhi Jain, Kunal Das, Prashant Verma, Anup Som, Rajashree Das
{"title":"过去二十年印度幽门螺杆菌的原发性抗生素耐药性:系统回顾。","authors":"Spriha Dutta,&nbsp;Surbhi Jain,&nbsp;Kunal Das,&nbsp;Prashant Verma,&nbsp;Anup Som,&nbsp;Rajashree Das","doi":"10.1111/hel.13057","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p><i>Helicobacter pylori</i> antibiotic resistance has undergone vast changes in the last two decades. No systematic review has been done on the prevalence of antibiotic resistant <i>H. pylori</i> in India in the last two decades. We evaluated the pattern of resistance rates across various regions of India.</p>\n </section>\n \n <section>\n \n <h3> Materials and Methods</h3>\n \n <p>A systematic review of the geographical variations in antibiotic resistance pattern of <i>H. pylori</i> was conducted using PubMed, Google Scholar, Web of Science, Science Direct, etc. for articles published between January 1, 2000 and May 30, 2023. Random effects-model-based Cochran's Q test, <i>I</i><sup>2</sup> statistics, and chi-squared tests were used to measure heterogeneity.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The overall resistance was highest against metronidazole (77.65%) followed by amoxicillin (37.78%), levofloxacin (32.8%), clarithromycin (35.64%), furazolidone (12.03%), and tetracycline (11.63%). 14.7% of the <i>H. pylori</i> isolates were multi-drug resistant. Under meta-analysis of each antibiotic, high heterogeneity levels were observed having <i>I</i><sup>2</sup> ranges from 86.53% to 97.70% at <i>p</i> &lt; 0.0001. In sub-group analysis, Metronidazole has a stable rate of resistance as compared to other antibiotics. Other antibiotics have had a downtrend in the last 5 years except for levofloxacin, which has had an uptrend in the resistance rate for the past 5 years. Hence, one should avoid using metronidazole for any kind of first-line treatment.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Metronidazole resistance is high in most regions of India except Assam and Mumbai while clarithromycin is found to be ineffective in South India, Gujarat, and Kashmir. As compared to other antibiotics, resistance to amoxicillin is generally low except in certain regions (Hyderabad, Chennai, and the Gangetic belt of North India). Tetracycline and Furazolidone have the least resistance rates and should be part of anti- <i>H. pylori</i> regimens. The resurgence of high single and multidrug resistance to the commonly used drugs suggests the need for newer antibiotics and regular resistance surveillance studies.</p>\n </section>\n </div>","PeriodicalId":13223,"journal":{"name":"Helicobacter","volume":"29 1","pages":""},"PeriodicalIF":4.3000,"publicationDate":"2024-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Primary antibiotic resistance of Helicobacter pylori in India over the past two decades: A systematic review\",\"authors\":\"Spriha Dutta,&nbsp;Surbhi Jain,&nbsp;Kunal Das,&nbsp;Prashant Verma,&nbsp;Anup Som,&nbsp;Rajashree Das\",\"doi\":\"10.1111/hel.13057\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p><i>Helicobacter pylori</i> antibiotic resistance has undergone vast changes in the last two decades. No systematic review has been done on the prevalence of antibiotic resistant <i>H. pylori</i> in India in the last two decades. We evaluated the pattern of resistance rates across various regions of India.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Materials and Methods</h3>\\n \\n <p>A systematic review of the geographical variations in antibiotic resistance pattern of <i>H. pylori</i> was conducted using PubMed, Google Scholar, Web of Science, Science Direct, etc. for articles published between January 1, 2000 and May 30, 2023. Random effects-model-based Cochran's Q test, <i>I</i><sup>2</sup> statistics, and chi-squared tests were used to measure heterogeneity.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>The overall resistance was highest against metronidazole (77.65%) followed by amoxicillin (37.78%), levofloxacin (32.8%), clarithromycin (35.64%), furazolidone (12.03%), and tetracycline (11.63%). 14.7% of the <i>H. pylori</i> isolates were multi-drug resistant. Under meta-analysis of each antibiotic, high heterogeneity levels were observed having <i>I</i><sup>2</sup> ranges from 86.53% to 97.70% at <i>p</i> &lt; 0.0001. In sub-group analysis, Metronidazole has a stable rate of resistance as compared to other antibiotics. Other antibiotics have had a downtrend in the last 5 years except for levofloxacin, which has had an uptrend in the resistance rate for the past 5 years. Hence, one should avoid using metronidazole for any kind of first-line treatment.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions</h3>\\n \\n <p>Metronidazole resistance is high in most regions of India except Assam and Mumbai while clarithromycin is found to be ineffective in South India, Gujarat, and Kashmir. As compared to other antibiotics, resistance to amoxicillin is generally low except in certain regions (Hyderabad, Chennai, and the Gangetic belt of North India). Tetracycline and Furazolidone have the least resistance rates and should be part of anti- <i>H. pylori</i> regimens. The resurgence of high single and multidrug resistance to the commonly used drugs suggests the need for newer antibiotics and regular resistance surveillance studies.</p>\\n </section>\\n </div>\",\"PeriodicalId\":13223,\"journal\":{\"name\":\"Helicobacter\",\"volume\":\"29 1\",\"pages\":\"\"},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2024-02-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Helicobacter\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/hel.13057\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Helicobacter","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/hel.13057","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:幽门螺杆菌的抗生素耐药性在过去二十年间发生了巨大变化。在过去二十年中,尚未对印度幽门螺杆菌的耐药性流行情况进行过系统回顾。我们评估了印度不同地区的耐药率模式:我们使用 PubMed、Google Scholar、Web of Science、Science Direct 等网站,对 2000 年 1 月 1 日至 2023 年 5 月 30 日期间发表的文章进行了系统综述,研究了幽门螺杆菌抗生素耐药模式的地域差异。采用基于随机效应模型的科克兰Q检验、I2统计量和卡方检验来衡量异质性:甲硝唑的耐药性最高(77.65%),其次是阿莫西林(37.78%)、左氧氟沙星(32.8%)、克拉霉素(35.64%)、呋喃唑酮(12.03%)和四环素(11.63%)。14.7%的幽门螺杆菌分离物具有多重耐药性。在对每种抗生素进行荟萃分析时,观察到了较高的异质性水平,其 I2 范围为 86.53% 至 97.70%,P 值为 结论:除阿萨姆邦和孟买外,印度大部分地区对甲硝唑的耐药性都很高,而克拉霉素在南印度、古吉拉特邦和克什米尔则无效。与其他抗生素相比,除了某些地区(海得拉巴、钦奈和北印度恒河带)外,阿莫西林的耐药性普遍较低。四环素和呋喃唑酮的耐药率最低,应作为抗幽门螺杆菌方案的一部分。对常用药物的高单药耐药性和多药耐药性的再次出现表明,有必要采用更新的抗生素并定期进行耐药性监测研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Primary antibiotic resistance of Helicobacter pylori in India over the past two decades: A systematic review

Background

Helicobacter pylori antibiotic resistance has undergone vast changes in the last two decades. No systematic review has been done on the prevalence of antibiotic resistant H. pylori in India in the last two decades. We evaluated the pattern of resistance rates across various regions of India.

Materials and Methods

A systematic review of the geographical variations in antibiotic resistance pattern of H. pylori was conducted using PubMed, Google Scholar, Web of Science, Science Direct, etc. for articles published between January 1, 2000 and May 30, 2023. Random effects-model-based Cochran's Q test, I2 statistics, and chi-squared tests were used to measure heterogeneity.

Results

The overall resistance was highest against metronidazole (77.65%) followed by amoxicillin (37.78%), levofloxacin (32.8%), clarithromycin (35.64%), furazolidone (12.03%), and tetracycline (11.63%). 14.7% of the H. pylori isolates were multi-drug resistant. Under meta-analysis of each antibiotic, high heterogeneity levels were observed having I2 ranges from 86.53% to 97.70% at p < 0.0001. In sub-group analysis, Metronidazole has a stable rate of resistance as compared to other antibiotics. Other antibiotics have had a downtrend in the last 5 years except for levofloxacin, which has had an uptrend in the resistance rate for the past 5 years. Hence, one should avoid using metronidazole for any kind of first-line treatment.

Conclusions

Metronidazole resistance is high in most regions of India except Assam and Mumbai while clarithromycin is found to be ineffective in South India, Gujarat, and Kashmir. As compared to other antibiotics, resistance to amoxicillin is generally low except in certain regions (Hyderabad, Chennai, and the Gangetic belt of North India). Tetracycline and Furazolidone have the least resistance rates and should be part of anti- H. pylori regimens. The resurgence of high single and multidrug resistance to the commonly used drugs suggests the need for newer antibiotics and regular resistance surveillance studies.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Helicobacter
Helicobacter 医学-微生物学
CiteScore
8.40
自引率
9.10%
发文量
76
审稿时长
2 months
期刊介绍: Helicobacter is edited by Professor David Y Graham. The editorial and peer review process is an independent process. Whenever there is a conflict of interest, the editor and editorial board will declare their interests and affiliations. Helicobacter recognises the critical role that has been established for Helicobacter pylori in peptic ulcer, gastric adenocarcinoma, and primary gastric lymphoma. As new helicobacter species are now regularly being discovered, Helicobacter covers the entire range of helicobacter research, increasing communication among the fields of gastroenterology; microbiology; vaccine development; laboratory animal science.
期刊最新文献
Helicobacter pylori Infection in Children: To Eradicate or Not to Eradicate? Helicobacter pylori Eradication Therapy and the Risk of Colorectal Cancer: A Population-Based Nationwide Cohort Study in Sweden Helicobacter pylori Management in Africa: A Survey of Diagnostic, Treatment, and Related Resources LCI's Diagnostic Performance for Gastric Cancer: A New Solution to Screening? Nationwide Trends in Helicobacter pylori Eradication Therapies in Korea: Impact of Guideline Updates on Treatment Practices
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1